Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：36
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [41] Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.
    Mulligan, Jude M.
    Hit, Laura A.
    Deharo, Steve
    Keating, Katherine E.
    Raji, Claude
    McOyer, Fionnuala A.
    James, Jacqueline
    Irwin, Gareth
    Boyle, David
    Quinn, Jennifer E.
    Mullan, Paul B.
    James, Colin R.
    Salto-Tellez, Manuel
    Davison, Timothy S.
    Johnston, Patrick
    Couch, Fergus J.
    Harkin, D. Paul
    Kennedy, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer
    Takala, Laura
    Barlund, Maarit
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Pirkko, Liisa
    ANTICANCER RESEARCH, 2019, 39 (01) : 279 - 283
  • [43] The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer
    Kota K.J.
    Brufsky A.M.
    Current Breast Cancer Reports, 2017, 9 (4) : 210 - 216
  • [44] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [45] ANTHRACYCLINE-BASED CHEMOTHERAPY FOR BREAST CANCER - PREDICTIVE FACTORS OF DOSE INTENSITY REDUCTION
    Faustino, C.
    Afonso, N.
    Sousa, B.
    Rodrigues, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 82 - 82
  • [46] More than half of breast cancer patients develop diastolic dysfunction after anthracycline-based chemotherapy
    Serrano, Jose M.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2015, 76 (08) : 443 - 443
  • [47] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Vargas-Roig, L. M.
    Cuello-Carrion, F. D.
    Fernandez-Escobar, N.
    Daguerre, P.
    Leuzzi, M.
    Ibarra, J.
    Gago, F. E.
    Nadin, S. B.
    Ciocca, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Menstrual disorders during anthracycline-based adjuvant chemotherapy in very young early breast cancer patients
    Neskovic-Konstantinovic, Z.
    Strbac, D.
    Susnjar, S.
    Vukotic, D.
    Gavrilovic, D.
    BREAST, 2007, 16 : S42 - S42
  • [49] Benefits of dexrazoxane in female patients with stage II breast cancer treated with anthracycline-based adjuvant chemotherapy
    Schnirer, I. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
    Nolan, Luke
    Darby, Angela
    Boleti, Katia
    Simmonds, Peter
    BREAST, 2011, 20 (02): : 151 - 154
12345